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Experimental studies in animals and humans
have shown that exposures to particulate air
pollutants on a time scale of minutes to several
hours can cause adverse respiratory effects.
However, there is no direct experimental eval-
uation of differences in biologic responses to
particulate air pollution (particulate matter;
PM) from time-varying exposures (with peaks)
versus time-invariant exposures controlling for
cumulative exposure. Biologic responses may
intensify with high peaks in concentrations of
pollutants that overwhelm certain lung defense
mechanisms. In epidemiologic research, daily
peak particle concentrations measured at cen-
tral outdoor sites may also serve as a better
indicator for personal outdoor exposures dur-
ing the daytime compared with daylong aver-
ages. Most epidemiologic studies have relied
on particle averaging times of 24 hr. There are
few epidemiologic studies examining respira-
tory effects from peak particle exposures (1,2).
The present epidemiologic study examined
effects of maximum hourly concentrations of
outdoor particulate matter < 10 µm in aerody-
namic diameter (PM10) on asthma symptoms
in children to assess the utility of peak versus
daily average exposure data.
Based on our previous findings (1), we
hypothesized that peak hourly exposures to
PM of outdoor origin will be more closely
associated with acute asthmatic symptoms in
some susceptible children than will 24-hr
average exposures. We further hypothesize
that the proinﬂammatory effects of air pollu-
tants will likely vary across individual asthmatic
children, with greater responses in those with
more severe disease. The severity of asthma
depends largely on the magnitude of underly-
ing pulmonary inﬂammation (3). Therefore,
subjects taking anti-inﬂammatory medications
may be protected against proinflammatory
effects of airborne agents and may show smaller
responses to air pollutants, including O3, nitro-
gen dioxide (NO2), and some particle compo-
nents. Experimental evidence in asthmatic
patients identiﬁes the proinﬂammatory effects
of O3 as a major mechanism for adverse effects
of O3 (4,5), and emerging experimental evi-
dence for particulate air pollution is beginning
to characterize the proinﬂammatory nature of
causal components [e.g., (6)].
In the present article, we again examine
the relationships of daily asthma symptom
severity to 1-hr maximum, 8-hr maximum,
and 24-hr mean PM10 measured March
through April 1996 in Alpine, California.
This panel study included 22 children with
asthma (9–19 years old) living in nonsmoking
households (1,248 person-days). Strengths of
association are compared between the differ-
ent particle averaging times. In addition,
strengths of association for the relationship of
asthma symptom severity to air pollutants
and aeroallergens are compared between
subgroups of asthmatic children divided into
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Maxima of hourly data from outdoor monitors may capture adverse effects of outdoor particulate
matter (PM) exposures in asthmatic children better than do 24-hr PM averages, which form the
basis of current regulations in the United States. Also, asthmatic children on anti-inﬂammatory
medications may be protected against the proinﬂammatory effects of air pollutants and aeroaller-
gens. We examined strengths of pollutant associations with asthma symptoms between subgroups
of asthmatic children who were on versus not on regularly scheduled anti-inﬂammatory medica-
tions, and tested associations for different particle averaging times. This is a daily panel study of
22 asthmatic children (9–19 years of age) followed March through April 1996 (1,248 person-
days). They lived in nonsmoking households in a semirural area of Southern California within the
air inversion mixing zone (range, 1,200–2,100 feet) with transported air pollution from urban
areas of Southern California. The dependent variable derived from diary ordinal scores is episodes
of asthma symptoms that interfered with daily activities. Minimum to 90th-percentile levels of
exposures at the outdoor monitoring site were 12–63 µg/m3 for 1-hr PM < 10 µm in aerodynamic
diameter (PM10); 8–46 µg/m3 for 8-hr PM10; 7–32 µg/m3 for 24-hr PM10; 45–88 ppb for 1-hr
O3; 6–26 ppb for 8-hr NO2; 70–4,714 particles/m3 for 12-hr daytime fungi; and 12–744 parti-
cles/m3 for 24-hr pollen. Data were analyzed with generalized estimating equations controlling for
autocorrelation. There was no confounding by weather, day of week, or linear time trend.
Associations were notably stronger in 12 asthmatic children who were not taking anti-inﬂamma-
tory medications versus 10 subjects who were. Odds ratios (95% conﬁdence intervals) for asthma
episodes in relation to lag 0 minimum to 90th-percentile pollutant changes were, respectively, 1-
hr maximum PM10, 1.92 (1.22–3.02) versus 0.96 (0.25–3.69); 8-hr maximum PM10, 1.68
(0.91–3.09) versus 0.75 (0.18–3.04); 24-hr average PM10, 1.35 (0.82–2.22) versus 0.80
(0.24–2.69); 1-hr maximum O3, 1.28 (0.75–2.17) versus 0.76 (0.24–2.44); 8-hr maximum NO2,
1.91 (1.07–3.39) versus 1.08 (0.30–3.93); 12-hr fungi, 1.89 (1.24–2.89) versus 0.90 (0.35–2.30);
24-hr pollen, 1.90 (0.99–3.67) versus 0.85 (0.18–3.91). Pollutant associations were stronger dur-
ing respiratory infections in subjects not on anti-inﬂammatory medications. Although lag 0 1-hr
maximum PM10 showed the strongest association, the most robust associations were for lag 0 and
3-day moving averages (lags 0–2) of 8-hr maximum and 24-hr mean PM10 in sensitivity analyses
testing for thresholds. Most pollutant effects were largely driven by concentrations in the upper
quintile. The divergence of exposure–response relationships by anti-inﬂammatory medication use
is consistent with experimental data on inflammatory mechanisms of airborne pollutants and
allergens. Key words: asthma, epidemiology, longitudinal data analysis, ozone, panel study, partic-
ulate air pollution. Environ Health Perspect 110:A607–A617 (2002). [Online 13 September 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110pA607-A617delﬁno/abstract.htmla) those who were taking regularly scheduled
anti-inflammatory medications during the
panel follow-up period and b) those who did
not take anti-inﬂammatory medications. This
study was conducted in the same region as
the above-cited study (1), a semirural area of
southern California around the small town of
Alpine that lies within the air inversion mix-
ing zone (town elevation, 1,800 ft; range,
1,200–2,100 ft) with transported air pollu-
tion from urban areas of southern California.
The “early spring season” of March through
April was chosen because it is the peak pollen
period in southern California. This time
period differs from those of our previous
studies, when low pollen concentrations were
found and no pollen effects were seen (1,7,8).
This provided us the opportunity to examine
differences in response to pollen by subject
medication use and to test putative interac-
tions between O3 and pollen in relation to
asthma outcomes (9,10).
Methods
Design. The present design is a panel study,
which involves repeated measurements of out-
comes and exposures in individuals. The
repeated measurements make it possible to
establish, with some detail, the temporality of
causal associations and to examine acute expo-
sure–response relationships at the level of an
individual subject. Subjects can act as their own
control over time, analogous to a clinical
crossover trial. Panel designs with a large num-
ber of repeated measures can be an efficient
way to maximize information derived from a
small number of subjects. Power and precision
can be enhanced because the repeated measures
reduce the variability of the response variable
compared with strictly between-subject com-
parisons, without reducing the magnitude of
the true exposure–response relationships (11).
Population. The institutional review
boards of the University of California, Irvine,
San Diego State University, and Kaiser
Permanente approved the study protocol.
Informed written consent was obtained from
all subjects and one of their legal guardians.
Recruitment of subjects was done with the
assistance of the Alpine School District nurse
(four grade schools), with referrals from the
Kaiser Permanente Health Plan, Inc., San
Diego Area, Department of Allergy, and with
newspaper advertisements. Monetary incen-
tives were an essential component of both
recruiting and retaining subjects. Subjects
were not blinded to the study but were sim-
ply told that it involved the examination of
environmental agents, including outdoor
allergens. Eligibility criteria were as follows:
a) physician-diagnosed asthma with ≥ 1-year
history, including episodic symptoms of
wheezing, cough, and dyspnea; b) a history of
at least several weeks during the warm seasons
(March–October) when the subject required
the use of prescribed asthma medications for
asthma exacerbations apart from respiratory
infections; c) age from 9 to 18 years; d) home
and school addresses in the Alpine or adjacent
areas; and e) no history of smoking by the
subject and no person smoking in the sub-
ject’s home. One participant was recruited at
age 18 but turned 19 at the panel follow-up.
Twenty-ﬁve asthmatic children agreed to
participate, 16 boys and 9 girls. A 10-year-old
boy and a 17-year-old girl dropped out after
the second week of study and are not retained
for analysis. Remaining subjects were 18
white non-Hispanic Americans, 3 Hispanic
Americans, and 2 Asian Americans. One
white 10-year-old male was asymptomatic
throughout the panel period and therefore
contributed no information to the repeated-
measures analysis. This subject is not
included in the following analyses involving
22 subjects. Subjects lived an average of 1.9
miles (SD, 0.22) from the central site, rang-
ing from 0.6 to 2.9 miles, except one subject
at 5.45 miles. The panel period was 1 March
through 30 April 1996 (61 days). Subjects
were followed up weekly during the ﬁrst 2–3
weeks, then biweekly at their home to check
the accuracy of diaries and compliance with
the study protocol and to ask questions of
subjects and resolve problems. Two subjects
started in the second week of March, and all
volunteers completed the full follow-up
through March and April 1996. Missing
symptom score data occurred on 51 person-
days (3.8% of total expected follow-up of
1,328 person-days) because subjects had left
the study area all day, and on 29 person-days
because of noncompliance with diary comple-
tion (2.2%), leaving 1,248 person-days of
observation.
Classification of allergy among subjects
was based on the presence or absence of posi-
tive allergen reactivity as assessed using epicu-
taneous skin prick tests (SPTs) for house dust
mites, cat, and various pollens and molds
common to the study area (12). Positive SPT
reactivity was deﬁned as a wheal 3 mm greater
than the saline control or having a diameter ≥
50% of a histamine dihydrochloride control.
The SPTs for locally relevant pollens consisted
of standardized allergen extracts of nine trees,
Bermuda grass, a grass mix without Bermuda
grass, and two weed mixes. There were 13
SPTs for fungal spore taxa.
Asthma diary. At the end of each day,
subjects recorded medication use, presence of
respiratory infection or allergic rhinitis symp-
toms (hay fever), and the maximum level of
asthma symptom severity since the last entry
on the previous evening. Asthma symptoms
served as the main outcome variable in this
article. Our diary questions concerning
asthma symptoms focused on the impact of
the clinical severity of asthma on a subject’s
normal daily activities. Subjects received train-
ing in interpreting the scoring system so that it
was meaningful in relation to their activities
and asthma. This is important because of
interindividual differences in the types and
characteristics of symptoms recognized or
experienced by asthmatic patients. The
approach used combines the rating of various
symptoms into one score that is relevant to
the impact of asthma on a subject’s daily 
well-being. Asthma symptoms (cough,
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Table 1. Descriptive statistics for 22 asthmatic subjects, 1 March through 30 April 1996, Alpine, California.
On anti-inﬂammatory medication
Subject characteristic Yes (n = 10) No (n = 12)
Median age (age range, years) 12.5 (9–17) 15.0 (11–19)
No. males/females 6/4 8/4
No. allergic to fungi or pollen 8 9
No. days at symptom score (%)
0: No asthma symptoms present 282 (49.4) 241 (35.6)
1: Asthma symptoms present but caused no discomfort 160 (28.1) 149 (22.0)
2: Asthma symptoms caused discomfort but did not
interfere with daily activities or sleep 42 (7.4) 178 (26.2)
3: Asthma symptoms interfered somewhat with
daily activities or sleep 74 (13.0) 105 (15.5)
4: Asthma symptoms interfered with most activities (may
have stayed home in bed, returned home early from school,
or called a doctor or nurse for advice) 11 (1.9) 5 (0.7)
5: Asthma symptoms required going to a hospital,
emergency department, or outpatient clinic 1 (0.2) 0 (0)
Missing days (subject range) 40 (0–12) 40 (0–16)
Average symptom score (range) 0.90 (0.05–3.1) 1.24 (0.15–2.4)
No. asthma episodesa/person-days (%) 86/570 (15) 110/678 (16)
No. subjects with mild persistent or more severe asthma (%)b 2 (20.0) 6 (50.0)
No. subjects with any respiratory infections (%) 5 (50) 6 (50)
No. days with any respiratory infections (%)/subject range 24 (4.2)/0–10 46 (6.8)/0–18
Mean daily as-needed β-agonist inhaler puffs (SD) 1.47 (2.34) 1.01 (1.57)
aDefined as having asthma symptoms that interfered with daily activities (symptom score > 2). bDefined as daily diary
reports of bothersome symptoms or worse more than twice a week throughout the study (16), irrespective of asthma
medication regimen. wheeze, sputum production, shortness of
breath, and chest tightness) were rated by the
subjects according to their global severity on a
scale from 0 to 5. Our classiﬁcation, which we
developed for use in previous studies (1,7,8),
supplants the usual asthma panel study
approach of dichotomizing each individual
symptom into present or absent. Subjects clas-
siﬁed their asthma symptom severity across six
levels, as described in Table 1 (see “Results”).
For the purposes of this article, we will say “on
versus not on anti-inﬂammatory medications”
when comparing those who were taking regu-
larly scheduled anti-inﬂammatory medications
with those who did not take anti-inﬂammatory
medications. Rather than using prescribed
medications at baseline, the grouping was ascer-
tained by examining regular daily or near-daily
medication use, which subjects entered into
their diaries by medication name. Subjects and
parents were assisted in labeling medication
entry lines, and any changes were evaluated
during follow-up home visits. Twelve subjects
who were classiﬁed as not using anti-inﬂamma-
tory medications reported no use during the
panel follow-up period. For 10 subjects on reg-
ularly scheduled preventive medications, four
used inhaled cromolyn or nedocromil sodium,
and six used inhaled corticosteroids.
Subjects also entered yes or no regarding
whether they had a respiratory infection that
day. Diary instructions below the question
stated: “Were any of the following conditions
present today: a cold, sore throat, fever, doctor-
diagnosed flu, doctor-diagnosed respiratory
infection (pneumonia, bronchitis, croup,
pharyngitis, laryngitis, tracheitis, middle ear
infection, upper respiratory tract infection, or
sinus infection)?” This question was distin-
guished from a preceding question on allergy
symptoms that asked the yes or no question
“Did you have symptoms of hay fever today,
which were not due to a cold or flu?”
Instructions clarifying the hay fever question
stated: “Those symptoms should include more
than one of the following: sneezing, runny nose
(including postnasal drip), sinus or nasal con-
gestion, itchy and watery eyes, itchy throat.”
Environmental variables. The PM10 con-
centrations were measured with a tapered-ele-
ment oscillating microbalance (TEOM), at a
stationary outdoor monitoring station located
centrally in Alpine and operated by the San
Diego Air Pollution Control District
(SDAPCD). The TEOM is an inertial instru-
ment that measures particle mass in real time
on an exchangeable ﬁlter cartridge by monitor-
ing frequency changes of a tapered element
(13). The PM10 data were used as 1-hr aver-
aged data, similar to O3 monitoring, but in
contrast to the standard 24-hr PM10 collected
on filters and weighed on a scale. The U.S.
Environmental Protection Agency has certiﬁed
the TEOM for measuring PM10 concentration.
The TEOM sampler inlet was operated at 16.7
L/min, and the inlet air stream was heated to a
constant 50°C to keep water in the vapor phase.
We did not collect samples for daily gravimetric
mass, particle composition, or size fractions.
Sampling, analysis, and data-processing proto-
cols for PM10 were carried out as part of another
ongoing project at the University of Southern
California (14). Five days of TEOM data were
missing because of equipment malfunction. At
the same central site, outdoor O3 was moni-
tored continuously using ultraviolet photome-
try, and outdoor NO2 was monitored
continuously using chemiluminescence. Hourly
temperature, relative humidity, and wind speed
and direction were also measured there.
Measurements of aeroallergens were made
using the Burkard 7-day recording volumetric
pollen and fungal spore collector with a sample
ﬂow rate of 10 L/min (Burkard Manufacturing
Co. Ltd., Rickmansworth, Hertfordshire,
England). Placement of the pollen and fungal
spore sampler at the SDAPCD site ensured
no nearby upwind obstructions and was 4 m
above the ground. To prepare the sampler for
pollen and fungal spore collection, Melenex
tape was placed on the mounted drum of the
sampler and coated with silicone solution
evenly applied with an artist’s brush. After 7
days of continuous sample collection, the
tape was cut and mounted onto microscope
slides as 14 12-hr segments from 0900 hr to
2100 hr for daytime counts and 2100 hr to
0900 hr for nighttime counts. The various
fungal spores and pollen grains were then
counted and identiﬁed by using a compound
microscope at 500× and 1,000×. The pollen
and fungal spore counts were then converted
into particles per cubic meter of air for each
12-hr time period. One day of data was lost
because of slide damage. Two analytic vari-
ables were the total fungal spore and total
pollen concentrations, which were the sum of
the daily concentrations of all identiﬁed and
unidentiﬁed types of each of these two aller-
gen groups. The airborne exposure variables
in regression models were outdoor ambient
measurements of 1-hr and 8-hr maximum
and 24-hr mean PM10, 1-hr and 8-hr maxi-
mum O3 and NO2, and 12-hr daytime mean
and 24-hr daily mean total fungal spore and
total pollen concentrations.
Statistical analysis. We used descriptive
statistics on individual subjects to summarize
the severity of asthma symptoms over time.
We examined temporal trends for daily and
hourly pollutant concentrations and con-
structed exposure correlation matrices for pol-
lutant and weather variables to assess the
potential for confounding or multicollinearity
in regression analyses.
We used the asthma symptom score to
create a dichotomous response variable
representing the occurrence of clinically
meaningful asthma episodes: “no episode,” no
asthma symptoms, symptoms not bother-
some or not interfering with daily activities
(score < 3); versus “episode,” symptoms that
interfered somewhat with daily activities or
worse (score ≥ 3). 
A cut point between a score of 0 and 1
was not informative, probably because symp-
toms not considered by the subject to be
bothersome (score = 1) may not be clinically
meaningful. A cutoff point between a score of
1 and 2 was examined in regression models.
Regression parameters for this binary variable
versus exposures were consistent with but
smaller than the episode cutoff point.
Therefore, results presented are for the analy-
sis of asthma symptom episodes only.
We performed regression analyses of
effects of air pollutants on binary symptom
scores using generalized estimating equations
(GEEs). The GEE approach can model non-
normal response data that are discrete and cor-
related (15). The present data are correlated
because repeated daily measurements over
time in each individual constitutes a cluster of
dependent observations. The GEE models
were tested using the logit link in the SAS
(version 8; SAS Institute, Cary, NC) general-
ized linear model procedure Genmod, which
uses a ridge-stabilized Newton-Raphson algo-
rithm to maximize the log-likelihood function
for the regression parameters. Deviance statis-
tics for GEE models were used to assess the ﬁt
of various models. GEE models for the time-
varying predictors (air pollutants) were best
fitted with an autoregressive lag 1 working
correlation matrix. Serial correlation was thus
accounted for to control autocorrelation of
residual errors, a potential source of bias. The
GEE model for medication group alone, a
time-invariant predictor, was best ﬁtted with
an exchangeable correlation. We evaluated the
potential for confounding by temperature, rel-
ative humidity, day-of-week trends, linear
time trend across the 61 days, and upper or
lower respiratory infection. This was done
after testing for interaction with the pollutant
or aeroallergen variables. Confounding was
deﬁned as at least a 15% change in the para-
meter estimate. Two-pollutant and pollutant-
aeroallergen models were also examined after
testing for interaction. Model regression para-
meters were multiplied by an increase in the
pollutant of interest from the minimum to the
90th percentile of its distribution. The magni-
tude of effect is expressed as the symptom
odds ratios (ORs) for this increase to express
what may be among the largest effects for the
study population.
We ﬁrst performed regression analyses on
all subjects with single pollutants in the
model. We then tested for interaction
between whether a subject was on versus not
on anti-inﬂammatory medications and each of
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pared the regression coefﬁcients of subjects on
anti-inﬂammatory medications with those not
on anti-inﬂammatory medications to test the
null hypothesis of no difference in regression
coefficients between the two groups. To do
this analysis, we ﬁrst made a dummy variable
for medication group that is coded 1 for sub-
jects on anti-inﬂammatory medications and 0
for those not on anti-inflammatory medica-
tions. We then used the pollutant variable,
medication group, and a product term
between pollutant variable and medication
group as predictors in the regression equation.
We present disaggregated effects for the two
subgroups from this model.
The analysis focuses on effects of air pollu-
tant concentrations on the day of symptom
reports (lag 0). We also examined effects of air
pollution levels on days before the day of the
diary symptom report to assess the potential
for delayed or cumulative air pollutant health
effects. This was accomplished by regressing
symptoms on pollution levels measured up to
5 days before the day of symptom reporting
(lags 1–5). We then examined moving pollu-
tant averages that combined air pollution lev-
els on current and lag days. The moving
average length was chosen after examining the
distribution of individual day lag effects.
Because pollutants were measured on 5 days
before the start of the study, it was possible to
test lag effects from the ﬁrst day of follow-up.
However, lags and moving averages for PM10
were missing for up to 5 days after the time
the TEOM was malfunctioning.
Results
Descriptive statistics. Table 1 shows the char-
acteristics of subjects. We compared the two
groups on versus not on anti-inflammatory
medications. Subjects on anti-inflammatory
medications were somewhat younger than
other subjects, and in both groups there were
more boys than girls, which is the typical gen-
der distribution in pediatric asthma. Most
subjects were allergic to pollens or molds.
The overall proportion of days with asthma
episodes was similar between the two medica-
tion groups (15–16%). Two subjects on anti-
inflammatory medications had no episodes,
and one subject not on anti-inflammatory
medications had no episodes. We also used
daily symptom reports to classify a subject’s
asthma severity in a manner consistent with
the National Heart, Lung, and Blood
Institute (NHLBI) symptom-based criteria
(16), irrespective of asthma medication regi-
men. Subjects with mild persistent or more
severe asthma were defined as having daily
diary reports of bothersome or more severe
symptoms (score > 1) more than twice a week
throughout the study. Remaining subjects
were considered to have mild intermittent
asthma. There were more subjects not taking
anti-inﬂammatory medications who ﬁtted the
NHLBI classification of persistent asthma.
However, there was no signiﬁcant difference
in GEE models for medication classification
predicting either symptom scores > 1 or
symptom scores > 2 (p > 0.16). An equal pro-
portion of subjects in the two groups reported
respiratory infections. There was no signifi-
cant difference in use of as-needed β-agonist
inhalers between anti-inflammatory medica-
tion groups (Table 1).
Table 2 describes the exposure concentra-
tions. No days had ozone concentrations >
120 ppb, which is the current U.S. National
Ambient Air Quality Standard (NAAQS)
(17). PM10 levels were very low compared
with urban areas of southern California. The
highest 24-hr mean PM10 was less that a
fourth of the current NAAQS of 150 µg/m3
(17). As expected, the PM10 data show differ-
ent distributions depending on the averaging
time. The highest 24-hr mean PM10 mea-
surement was 42 µg/m3, compared with the
mean of 1-hr maximum PM10 of 38 µg/m3.
Levels of NO2 were fairly modest, with the
highest 1-hr maximum just reaching the
NAAQS for the annual arithmetic mean (53
ppb) (17). Looking at the overall average by
hour of day, we found the highest PM10
hourly exposures were from 1300 to 2000 hr
(> 22 µg/m3). The highest O3 hourly expo-
sures were from 0100 to 1700 hr (> 50 ppb).
These are times when children are most likely
to be outdoors and playing. Figure 1 shows
time plots of selected pollutant measurements
across the days of study.
The exposure correlation matrix is shown
in Table 3. Variables were approximately
normally distributed, so Pearson correlation
coefﬁcients were computed. Because of pho-
tochemical oxidation processes, both O3 and
PM10 are often jointly higher on hotter and
dryer days, which explain the correlations
among the pollutant and weather variables.
Pollen was also moderately correlated with O3
and PM10 because pollination of many native
plants is greatest on hot, dry days. In our region
of study, the months of March and April stud-
ied represent the period of greatest pollination.
Fungal concentrations were significantly but
weakly correlated with the pollutants. PM10
was moderately correlated with NO2, showing
that upwind combustion sources from urban
areas of southern California (largely traffic
related) are important.
Regression analysis. Single-pollutant
regression models. Symptoms were not asso-
ciated with day of week, linear trend, tempera-
ture, or relative humidity, and these variables
did not confound exposures. Models testing
lag days for aeroallergens, for PM10, and for
the gaseous pollutants were not signiﬁcant in
regression models fitted with each exposure
alone, including 1–5 days before the day of
symptom reports (lags 1–5). The largest and
most robust effects were found for exposures
on the same day (lag 0) of the subject’s asthma
symptom report. However, findings in a
regression model fitted with a product term
for anti-inﬂammatory medication by exposure
showed lag effects for the group not on anti-
inﬂammatory medications. Effects were sug-
gested for PM10 at lags 1 and 2 (p < 0.1), with
robust associations for the 3-day moving aver-
age of PM10 lags 0–2. Therefore, for simplic-
ity, models are presented for lag 0 and the
3-day moving average of PM10 for each of the
daily averaging times (maximum 1-hr, maxi-
mum 8-hr, and 24-hr mean). Lag 0 effects of
12-hr daytime total fungi were slightly greater
than 24-hr average total fungi, whereas effects
of 24-hr total pollen were slightly greater than
12-hr daytime total pollen. Therefore, for
simplicity, models are presented for 12-hr
total fungi and 24-hr total pollen.
There was no association between symp-
toms and medication group in a GEE model
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Table 2. Daily air pollution and weather measurements, 1 March through 30 April 1996, Alpine, California.a
No.
Exposure and averaging time observations Mean (SD) Min/max 90thpercentile
PM10 1-hr max (µg/m3)b 56 38 (15) 12/69 63
PM10 8-hr max (µg/m3)5 6 28 (12) 8/57 46
PM10 24-hr mean (µg/m3)5 6 20 (9) 7/42 32
O3 1-hr max (ppb) 61 69 (16) 45/108 88
O3 8-hr max (ppb) 61 60 (12) 39/97 75
NO2 1-hr max (ppb) 61 24 (10) 8/53 42
NO2 8-hr max (ppb) 61 15 (7) 6/34 26
Fungi 12-hr daytime mean (particles/m3)c 60 3,132 (1,647) 70/8,147 4,714
Fungi 24-hr mean (particles/m3)6 0 2,973 (1,542) 757/7,975 5,380
Pollen 12-hr daytime mean (particles/m3)6 0 427 (314) 17/1,310 875
Pollen 24-hr mean (particles/m3)6 0 345 (292) 12/1,257 744
Temperature 1-hr max (°F) 61 71 (10) 50/91 85
Relative humidity 24-hr mean (%) 61 59 (24) 12/97 86
Abbreviations: max, maximum; min, minimum.
aMeasurements were taken at the stationary outdoor monitoring site of the SDAPCD. bFive days are missing because of
TEOM equipment malfunction. c12-hr levels for fungi and pollen are for the sampling period of 0900 to 2100 hr; 24-hr levels
for fungi and pollen are from 2100 hr of the previous day to 2100 hr of the current day. One day is missing because of slide
damage.that included only a medication indicator
variable: OR = 1.06; 95% conﬁdence interval
(CI) = 0.25–4.43. However, we found signiﬁ-
cant interactions between exposures (air pol-
lutants or aeroallergens) and classiﬁcation of
subjects by regular use versus nonuse of anti-
inflammatory medications. Therefore, we
present GEE models without the product
term of medication group by pollutant con-
centration (model 1) to serve as a comparison
for relationships disaggregated by medication
use (Table 4, model 2). GEE results for the
models with each pollutant alone (model 1)
show that the lower 95% confidence limits
fall below 1.00 for relationships between
symptoms and pollutants or aeroallergens.
Nevertheless, several models suggest that risk
of an asthma symptom episode is greater with
elevations in exposures, including 1-hr maxi-
mum PM10, 3-day moving averages of all
PM10 daily averaging times, NO2, and the
aeroallergens. Exposure–response relation-
ships in model 2 are presented separately for
the two medication groups in Table 4. For all
pollutants and aeroallergens, ORs were larger
for subjects not taking anti-inflammatory
medications. A divergence in effects is sug-
gested for all models, with several showing
signiﬁcant between-group product terms (p <
0.05). In summary, results in Table 4 show
that only the group of children not on anti-
inﬂammatory medications had positive asso-
ciations between asthma symptoms and air
pollutants or aeroallergens. For all exposures
except O3 in this group, the lower 95% CIs are
either above 1.00 or do not fall far below 1.00.
Therefore, models below focus on this group to
test effects of multiple exposures and to test
sensitivity to high concentrations. Subgroup
models for these subjects showed narrower con-
ﬁdence limits for every exposure. For instance,
asthma symptoms were more clearly associated
with O3 (OR, 1.45; 95% CI, 0.97–2.11), and
the lower 95% conﬁdence limits for 8-hr PM10
and 24-hr pollen were above 1.00.
Symptoms were not associated with day of
week, linear trend, temperature, or relative
humidity in either model 1 or model 2.
Inclusion of temperature in the models led to
instability in all variance estimates, suggesting
problems of multicollinearity, but did not
confound air pollution variables. Deviance
was not substantially changed (deviance differ-
ence < 4.0) when adding day of week, linear
trend, temperature, or relative humidity to
models with the exposure alone. Symptoms
were associated with respiratory infections in
both groups: for the group not on anti-inﬂam-
matory medications, OR = 2.80 (95% CI,
0.92–8.49), and for the group on anti-
inﬂammatory medications, OR = 1.93 (95%
CI, 1.01–3.71). In exposure models including
respiratory infections, parameter estimates
shown in Table 4 increased in all models for
the group not on anti-inﬂammatory medica-
tions. However, we found signiﬁcant interac-
tions between exposures and respiratory
infections, making it more informative to pre-
sent the magnitude of increase in the ORs for
exposure given the presence versus absence of
a respiratory infection among subjects not on
anti-inflammatory medications (Table 5).
ORs were around three times greater or more
during respiratory infections than at other
times for all exposures except total pollen
(OR, 0.95). Pollutant exposures were not
associated with risk of respiratory infections in
GEE models, suggesting that risk of infection
onset was independent of the exposures, but
the probability of an asthmatic response to
respiratory infection was enhanced on high air
pollution days.
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Figure 1. Time plot of air pollutant exposures, (A) PM10 and (B) 03 and NO2, Alpine, California, panel study,
1 March through 30 April 1996. 
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Table 3. Air pollution and weather correlation matrix,a 1 March through 30 April 1996, Alpine, California.
8-hr max 1-hr max 8-hr max 24-hr mean 1-hr max 8-hr max 12-hr daytime 24-hr
O3 PM10 PM10 PM10 NO2 NO2 fungib pollenb Max temp 24-hr mean RH
1-hr max O3 0.95# 0.68# 0.72# 0.74# 0.31* 0.36** 0.30* 0.56# 0.76# –0.49#
8-hr max O3 0.62# 0.65# 0.71# 0.25 0.26* 0.26* 0.57# 0.76# –0.52#
1-hr max PM10 0.93# 0.84# 0.49# 0.55# 0.24 0.47# 0.69# –0.34*
8-hr max PM10 0.95# 0.48# 0.55# 0.28* 0.45# 0.66# –0.23
24-hr PM10 0.37** 0.44# 0.21 0.47# 0.64# –0.17
1-hr max NO2 0.91# 0.29* 0.27* 0.33** –0.28*
8-hr max NO2 0.32* 0.28* 0.36** –0.28*
12-hr fungi 0.29* 0.12 –0.07
24-hr pollen 0.68# –0.50#
Max temp –0.75**
Abbreviations: max, maximum; RH, relative humidity; temp, termperature. 
aPearson correlation coefﬁcients (p-value); n is 61 for O3, NO2, and weather, 60 for fungi and pollen, and 56 for PM10 observations. bCorrelations for 24-hr fungi and 12-hr pollen were sim-
ilar. *p < 0.05; **p < 0.01; #p < 0.001.Multiple exposure regression models. For
the group not on anti-inﬂammatory medica-
tions, we then tested multivariate models
involving multiple exposures. The aim was to
explore possible copollutant confounding and
interactions. This information could indicate
underlying effects of an air pollutant mixture
not fully captured by any one criteria air pol-
lutant. Regressions of two air pollutants gener-
ally led to decreases in both regression
parameters, likely the result of multicollinear-
ity. For example, the model including both
8-hr PM10 and 8-hr NO2 showed ORs
(95% CIs) of 1.19 (0.75–1.88) and 1.50
(0.80–2.82), respectively. Differences in the
fit of single-pollutant versus two-pollutant
models were not significant. However, there
were signiﬁcant positive multiplicative interac-
tions between the pollutants, which make
interpretation of the simple joint regression
models difﬁcult. The interaction was signiﬁ-
cant between 1-hr maximum PM10 and 8-hr
maximum NO2 (p < 0.01). Figure 2 shows
this pollutant interaction in relation to the
probability of a symptom response on the ver-
tical axis (scaled to the log odds). The mesh
plot was smoothed using a Loess transform
function. For example, if 1-hr maximum
PM10 was 69 µg/m3 and 8-hr maximum NO2
was at 31 ppb, the predicted probability of an
asthma symptom response is 33%. This can
be compared with an overall average probabil-
ity during the study of 17% (105 asthma
episodes/622 person-days of PM10 and NO2
observations) in the 12 subjects not on anti-
inﬂammatory medications.
Regression models including O3 and any
one of the other pollutant variables led to a
greater decrease in the O3 parameter than in
the copollutant parameter (e.g., 1-hr maxi-
mum NO2, OR decreased from 1.93 to 1.81,
whereas 1-hr maximum O3, OR decreased
from 1.43 to 1.23). Differences in the fit of
single-pollutant versus this two-pollutant
model were not signiﬁcant. There was a dra-
matic decrease in the O3 regression parameter
when regressed with PM10, which did not
change from the model with PM10 alone [e.g.,
1-hr maximum PM10, OR = 1.73 (95% CI,
1.03–2.92); 1-hr maximum O3, OR = 0.99
(95% CI, 0.56–1.77)]. There were no signiﬁ-
cant product terms of PM10 or NO2 with O3;
however, there was a suggestion of a positive
interaction between O3 and NO2 (p = 0.12).
The interaction is shown in Figure 3 in rela-
tion to the probability of a symptom response
on the vertical axis (scaled to the log odds).
Models including pollutants and aeroal-
lergens. We also tested multivariate models
including pollutants and aeroallergens for the
group not on anti-inﬂammatory medications.
Joint regression models were tested for pollu-
tants and total pollen in nine pollen-allergic
subjects and for pollutants and total fungi in
eight fungus-allergic subjects. Only one of the
pollen-allergic subjects was not in the fungus-
allergic group. Effect magnitudes for aeroaller-
gens were greater in the allergic group than in
all 12 subjects not on anti-inﬂammatory med-
ications, but differences were small (~15%).
There were no signiﬁcant multiplicative inter-
actions between the aeroallergens and pollu-
tants. Including both aeroallergens and air
pollutants in the same model generally led to a
decrease in regression parameters for both
exposures. In the case of regressions of total
pollen with O3, or with any of the 3-day mov-
ing averages of PM10, all standard errors were
inﬂated by over two times, suggesting multi-
collinearity. The aeroallergens did not con-
found the product term for O3 and NO2 or
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Table 4. Effect modiﬁcation by anti-inﬂammatory medication use on the relationship of asthma symptomsa in children to increases in PM10, O3, NO2, and aeroaller-
gen concentrations, Alpine, California panel study, 1 March through 30 April 1996.
OR (95% CI) per increase to 90th percentile of exposureb
Pollutant and  Model 2c
aeroallergen variables Exposure concentrationd Model 1e On medicationf Not on medicationg p-Valueh
1-hr max PM10 lag 0 51 µg/m3 1.41 (0.87–2.30) 0.96 (0.25–3.69) 1.92 (1.22–3.02)** 0.13
8-hr max PM10 lag 0 38 µg/m3 1.19 (0.74–1.94) 0.75 (0.18–3.04) 1.68 (0.91–3.09) 0.05
24-hr mean PM10 lag 0 25 µg/m3 1.08 (0.73–1.61) 0.80 (0.24–2.69) 1.35 (0.82–2.22) 0.15
3-day moving average 1-hr max PM10 51 µg/m3 1.45 (0.76–2.76) 1.01 (0.14–7.02) 1.92 (0.99–3.71) 0.33
3-day moving average 8-hr max PM10 38 µg/m3 1.32 (0.76–2.29) 0.82 (0.17–3.94) 1.89 (1.10–3.24)* 0.11
3-day moving average 24-hr mean PM10 25 µg/m3 1.22 (0.84–1.77) 0.75 (0.26–2.14) 1.75 (1.15–2.68)** 0.008
1-hr max O3 lag 0 43 ppb 1.02 (0.71–1.47) 0.76 (0.24–2.44) 1.28 (0.75–2.17) 0.11
8-hr max O3 lag 0 36 ppb 0.94 (0.64–1.40) 0.73 (0.20–2.67) 1.14 (0.62–2.09) 0.21
1-hr max NO2 lag 0 34 ppb 1.40 (0.80–2.47) 0.90 (0.17–4.78) 1.95 (0.88–4.32) 0.08
8-hr max NO2 lag 0 20 ppb 1.49 (0.95–2.33) 1.08 (0.30–3.93) 1.91 (1.07–3.39)* 0.12
12-hr fungi lag 0 4,644 particles/m3 1.37 (0.95–1.97) 0.90 (0.35–2.30) 1.89 (1.24–2.89)** 0.005
24-hr pollen lag 0 732 particles/m3 1.37 (0.84–2.21) 0.85 (0.18–3.91) 1.90 (0.99–3.67) 0.07
Max, maximum. 
aThe asthma symptom severity score was dichotomized to a) no symptoms or symptoms not bothersome or not interfering with daily activities, versus b) symptoms interfering with daily
activities. bGEE models involve 56 days for PM10, 61 days for O3 and NO2, and 60 days for aeroallergens; lag 0 concentrations are from the same day as the symptom reports. cPollutant,
indicator for medication group, and interaction term for pollutant by medication group. d90th percentile minus the minimum. ePollutant alone. fOn anti-inﬂammatory medications; six sub-
jects on inhaled corticosteroids and four subjects on cromolyn or nedocromil; total of 570 person-days of O3 and NO2 observations, 524 person-days of PM10 observations, and 560 per-
son-days of aeroallergen observations. gNot on anti-inﬂammatory medications; twelve subjects with 678 person-days of O3 and NO2 observations, 622 person-days of PM10 observations,
and 666 person-days of aeroallergen observations. hFor between-group product term in model 2. *p < 0.05; **p < 0.01.
Table 5. ORs for risk of asthma symptomsa from a 90th percentile increase in pollutants or aeroallergens in
those who report a respiratory infection compared with those who do not have respiratory infections. 
Pollutant and aeroallergen variables Air pollutant levelb OR (95% CI)c
1-hr max PM10 lag 0 51 µg/m3 4.88 (1.31–18.2)
8-hr max PM10 lag 0 38 µg/m3 6.78 (1.38–33.3)
24-hr mean PM10 lag 0 25 µg/m3 4.68 (0.71–30.7)
3-day moving average 1-hr max PM10 51 µg/m3 11.1 (1.10–112)
3-day moving average 8-hr max PM10 38 µg/m3 10.1 (1.42–72.0)
3-day moving average 24-hr mean PM10 25 µg/m3 2.67 (0.60–11.8)
1-hr max O3 lag 0 43 ppb 3.27 (1.00–10.7)
8-hr max O3 lag 0 36 ppb 2.72 (0.67–11.0)
1-hr max NO2 lag 0 34 ppb 3.46 (0.45–26.6)
8-hr max NO2 lag 0 20 ppb 6.72 (1.73–26.1)
12-hr fungi lag 0 4,644 particles/m3 6.38 (1.03–39.6)
24-hr pollen lag 0 732 particles/m3 0.95 (0.16–5.74)
Max, maximum. Effect modification of respiratory infection in children not on anti-inflammatory medications, Alpine,
California, panel study, 1 March through 30 April 1996.
aThe asthma symptom severity score was dichotomized to a) no symptoms or symptoms not bothersome or not interfering
with daily activities, versus b) symptoms interfering with daily activities. b90th percentile minus the minimum. cPer
increase to 90th percentile concentration of pollutant or aeroallergen given the presence vs. absence of a respiratory
infection from GEE models including the pollutant or aeroallergen, an indicator variable for respiratory infection and a
product term between them. Models involve 12 subjects with 678 person-days of O3 and NO2 observations, 622 person-
days of PM10 observations, and 666 person-days of aeroallergen observations.the product term for PM10 and NO2
described above.
Sensitivity analysis. Effects at low levels
of particulate air pollution and NO2 in the
present study may be surprising, whereas
there is some expectation of effects for O3
given that the 1-hr maximum approached the
NAAQS (17) (120 ppb) on 3 days (94–108
ppb). We did not identify any statistical out-
liers in pollutant distributions (> 3 SD above
the mean). However, it is possible that only
the highest concentrations drove associations.
Therefore, models for subjects not on anti-
inﬂammatory medications were further tested
by progressively dropping the upper 5% of
pollutant concentrations (2–3 days) to test for
a “threshold effect.” We found that dropping
the upper 5% of 1-hr maximum PM10 (2
days at 69 µg/m3) led to a marked reduction
in the OR from 1.72 to 1.27, but there was
little change in ORs for 8-hr maximum PM10
and 24-hr mean PM10. There were no
decreases in parameters for the 3-day moving
averages of PM10. Dropping the upper 10%
led to a further reduction in the OR for 1-hr
maximum PM10 to 0.97, but not for 8-hr
maximum PM10 or 24-hr mean PM10. Again,
the 3-day moving average PM10 effects
remained above an OR of 1.5. No reductions
in effect magnitudes were found after drop-
ping the upper 15% of 8-hr maximum PM10
or 24-hr mean PM10. Dropping the upper
15% of 3-day moving average PM10 variables
notably dropped the effect of the 1-hr maxi-
mum to an OR of 1.11, but not the 3-day 8-
hr maximum or the 3-day 24-hr mean.
Dropping the upper 5% also led to a
marked reduction in the OR for 1-hr maximum
O3 from 1.43 to 1.19 and for 8-hr maximum
NO2 from 1.73 to 1.17, and similar reductions
were seen for other averaging times. We found
no further reductions in ORs after dropping the
upper 10% of O3 and NO2. After we dropped
the upper 15%, the OR for NO2 dropped to
near unity, but O3 showed an increase. After we
dropped the upper 10% of PM10, NO2, and
O3, pollutant interactions noted above were still
signiﬁcant between PM10 and NO2 and were
borderline signiﬁcant (p < 0.1) between NO2
and O3. All of the pollutant interactions were
nonsigniﬁcant after dropping the upper 15%.
Dropping the upper 5% of fungal spores
did not reduce its effect (OR, 2.03), and the
same was found for total pollen (OR, 1.87).
Further dropping the upper 10% of fungal
spores markedly reduced the OR to 1.37, but
the reduction was less for total pollen (OR,
1.57). Dropping the upper 15% of fungi
eliminated any association (OR, 1.18; p =
0.7). However, dropping the upper 15% of
total pollen did not reduce the effect magni-
tude (OR, 1.82).
Further exclusions below the 15th per-
centile led to additional reductions in most
ORs and wide conﬁdence intervals below the
fifth quintile. Exceptions to this were found
for the 3-day moving average of 24-hr mean
PM10 and total pollen, which showed associa-
tions for the fourth compared with the lowest
quintile [PM10 OR = 1.93 (95% CI,
1.34–2.79); pollen OR = 1.50 (95% CI,
1.04–2.14)] but not the third quintile.
Discussion
Overview of ﬁndings. These ﬁndings conﬁrm
the acute adverse effects of air pollutants on
asthmatic symptoms and suggest that the irri-
tant potential of PM10 at inversion layer ele-
vations is greater than expected based upon
mass concentration. Our findings also point
to the potential relevance of peak PM10 expo-
sures to acute respiratory effects. Magnitudes
of association for current-day PM10 showed
modest graded differences of 1-hr maximum
> 8-hr maximum > 24-hr mean PM10.
However, confidence intervals overlapped
markedly, and findings for the 1-hr maxi-
mum were sensitive to removal of the two
highest days at 69 µg/m3.
Our strongest lag day associations for
PM10 were found with lag 0 (the current
day’s exposure) and a 3-day moving average.
Given that the time coarse of lung function
and symptom changes can be on the order of
minutes to hours for early- to late-phase asth-
matic reactions (18), asthma is expected to be
acutely related to airborne exposure on the
day of an exacerbation (lag 0). We found
slightly stronger associations with a 3-day
moving average than with lag 0 of 24-hr
mean PM10, suggesting some cumulative or
delayed effects as well. The lag 0 and multi-
day moving average findings are consistent
with results of our previous asthma panel
study during fall 1995 in the same region (1).
Sixteen of 22 subjects in the present study
were subjects in this previous study.
Associations of asthma symptoms with
PM10, NO2, O3, fungi, and pollen were
largely isolated to asthmatic children not tak-
ing anti-inﬂammatory medications, with sig-
nificant or near-significant differences in
regression slopes from subjects who were tak-
ing anti-inﬂammatory medications (Table 4).
This is consistent with a similar divergence of
association by anti-inﬂammatory medication
use found in our earlier asthma panel (1). The
present study also showed a further enhance-
ment of symptom responses to pollutant expo-
sures among subjects not on anti-inﬂammatory
medication during respiratory infections.
Asthma symptoms were more clearly asso-
ciated with O3 in a subgroup model including
only subjects not on anti-inﬂammatory med-
ications. Positive associations between asthma
outcomes and O3 have been consistently
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Figure 2. Predicted probability of an asthma symptom response and interaction between PM10 and NO2 in
asthmatics not on anti-inﬂammatory medications. The probability of a symptom response is on the vertical axis
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ereported in the literature (19) and in two of
our previous studies in the same region (1,7),
but not in another study in Alpine (8).
Asthma symptoms were associated with
combined elevations of NO2 and O3. This
suggests either a pollutant interaction or that
underlying effects of an air pollutant mixture
on days with joint elevations are not fully cap-
tured by any one of these criteria air pollutants.
In two-pollutant models, there was a loss of O3
association in joint regressions with PM10, but
this may have been caused by collinearity
effects. Signiﬁcant interactions were also found
between PM10 and NO2. Again, this suggests
that the product term represented either a pol-
lutant interaction or underlying effects of an
air pollutant mixture. Outdoor fungal and
pollen particles were associated with asthma
symptoms as well, but there were no interac-
tions with any air pollutant.
Results of testing for a threshold suggest
that effects from lag 0 1-hr maximum PM10,
O3, and NO2 were attributable primarily to
2–3 days of elevated concentrations for each
variable. For these days, one day showed both
higher PM10 and NO2 levels, and one day
showed both higher PM10 and O3 levels.
These were all warm, dry days with maxi-
mum temperatures from 74°F to 91°F and
minimum relative humidity from 11% to
26%. Winds were 2–3 mph, all out of the
west (urban areas). More days, including the
upper 15th percentile, were driving associa-
tions for lag 0 8-hr maximum PM10 and 24-
hr mean PM10, as well as the 3-day moving
averages of 8-hr average PM10 (down to 38
µg/m3). Effects were found down to the
fourth quintile for the 3-day moving average
of 24-hr average PM10 (20–23 µg/m3) and to
the fourth quintile of lag 0 pollen 345–590
particles/m3. Fungal spores had no effect
below the 90th percentile. Our aim in this
sensitivity analysis was to examine whether
there was an apparent threshold in the mod-
els. As stated above, higher concentrations
were not statistical outliers in pollutant distri-
butions. Results after discarding valid concen-
trations at the upper end of the pollutant
distribution were exploratory in nature. The
sensitivity analysis identiﬁed the need for both
a greater amount of data to model the shape
of the exposure–response curve and better
modeling strategies to determine that shape.
Limitations. The external validity of dif-
ferences in results by subjects on versus not
on anti-inflammatory medications is limited
by small numbers of subjects (10 vs. 12,
respectively). The major limitation in the pre-
sent study is reliance on outdoor central site
exposures to represent individual exposures.
The magnitude of exposure misclassiﬁcation is
expected to be greatest for the gaseous pollu-
tants. In the case of O3, this is because of low
indoor-to-outdoor concentration ratios. We
previously conducted an exposure assessment
study for two seasons (spring and fall 1994) in
Alpine using personal passive O3 badges. We
found relatively low correlations between per-
sonal (1,175 samples) and outdoor central site
O3 concentrations even after incorporating
time–activity, traffic, and spatial data in
microenvironmental models (adjusted R2 =
0.22 and 0.19 in the two seasons) (20). The
present study lacked personal exposure mea-
surements, although we aim to provide pre-
dictive PM10 data for this and earlier studies
using data from our ongoing investigations in
Alpine with personal real-time particle mea-
surements from nephelometers (21).
The present measurements of particle
exposures (PM10) were additionally limited
by an inability to separate ﬁne (PM2.5) from
coarse (PM2.5–10) particle fractions. Fine par-
ticles have been found to be a stronger predic-
tor of asthma-related responses than are
coarse particles in the Harvard Six Cities
Diary Study (22). This difference is expected
because the deposition fraction in the lower
respiratory tract and alveoli of the lungs is
greater for fine particles and because toxic
irritants in air pollution formed from com-
bustion and photochemical processes are gen-
erally found in the fine particle fraction
(SO4
2–, NO3
–, H+, metals, and organic com-
pounds). Nevertheless, coarse particle compo-
nents, including crustal elements and some
bioaerosols, may also be important respiratory
irritants for asthmatic patients. An additional
weakness in the PM exposure metric is that
TEOM measurements of PM10 could have
potentially underestimated concentrations at
key times because of the expected volatiliza-
tion of important semivolatile particle com-
ponents as they cross the 50°C heating
element (23).
Particle effects by hourly averaging time.
Our ﬁndings of modestly stronger effects for
shorter PM10 averaging times are tempered
by the fact that confidence intervals over-
lapped markedly and stronger effects of the 1-
hr maximum were driven by 2 of 56 observed
days whereas at least 8 days were driving asso-
ciations for 8-hr maximum PM10 and 24-hr
mean PM10. Also, there was no difference in
magnitude of association for the 3-day mov-
ing averages of the different PM10 variables,
and only the 8-hr and 24-hr PM10 3-day
moving averages maintained their effect mag-
nitudes after dropping up to 15% of the
highest values.
In our previous Fall 1995 panel study (1),
analyses in all 24 children showed statistically
significant risks of asthma symptoms from
increases in daily 1-hr and 8-hr maximum
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Figure 3. Predicted probability of an asthma symptom response and interaction between O3 and NO2 in asth-
matics not on anti-inﬂammatory medications. The probability of a symptom response is on the vertical axis










1-hr max NO2 (ppb)














































100PM10. Effects were smaller and nonsigniﬁcant
for the 24-hr PM10 average. However, sub-
group analyses showed this difference only in
10 more symptomatic asthmatic subjects,
only one of whom was on an anti-inﬂamma-
tory medication. Among less symptomatic
subjects, particle effects were generally weaker
for the 1-hr compared with the 8-hr maxi-
mum or 24-hr average. Dropping the upper
10% of observations did not alter these previ-
ous findings. One other asthma panel study
has examined hourly maximum PM10 mea-
sured using β-attenuation monitors. Ostro et
al. (2) reported results of an asthma panel
study of 138 African-American children liv-
ing in Los Angeles and Pasadena, California.
Diary reports of wheezing, cough, and dysp-
nea were associated somewhat more strongly
with a 17-µg/m3 increase in 24-hr PM10
(ORs, 1.04–1.25) than with a 31-µg/m3
increase in 1-hr PM10 (ORs, 1.02–1.07). No
results were presented for 8-hr maxima.
A reasonable biologic rationale for the
hypothesis that maximum hourly particle
exposures can induce asthmatic reactions is
that changes in personal particle exposure con-
centrations over the course of a day will alter
the dose of particles in the lung in a time-
dependent manner. Therefore, it is expected
that biologic responses may intensify with high
peak excursions that overwhelm lung defense
mechanisms (e.g., mucociliary transport, and
neutralization or metabolism of toxic sub-
stances). However, clinical data on the rele-
vance of particle averaging time to respiratory
responses is inadequate to support or refute
this rationale. A more defensible rationale for
epidemiologic research is that shorter averaging
times can be used as better surrogates for pop-
ulation exposures than daylong averages. Peak
particle excursions could occur during the day-
time when children are outdoors and physi-
cally active, thus leading to higher pulmonary
doses. The peak concentrations of PM10 in the
present study occurred between 1300 and
2000 hr. The ﬁnding that the most robust par-
ticle effects were for the 8-hr maximum expo-
sures over the current and prior 2 days could
be the result of maximal personal exposures
and doses occurring around the same 8-hr
time period. One-hour peaks may be more
influenced by local point sources near the
monitoring station that are not representative
of regional exposures, thus explaining weaker
associations with asthma symptoms for multi-
day 1-hr than for 8-hr maximum PM10 in the
present study as well as in our previous study
(1). Sustained high peaks during the day may
partly explain epidemiologic associations with
24-hr average PM10 at levels below the
NAAQS of 150 µg/m3 (24).
Effect modiﬁcation by anti-inﬂammatory
medication use. Our ﬁndings support the view
that proinﬂammatory components of PM are
causally related to acute asthma exacerbations.
In our earlier study, subjects on inhaled anti-
inflammatory medications during follow-up
(six on corticosteroids, one on cromolyn)
experienced fewer symptoms. To evaluate
effect modification by medication use, we
therefore compared them with seven other
subjects not on anti-inflammatory medica-
tions but with a similar frequency of asthma
symptom reports (1). The OR (95% CI) in
the previous report for a 36-µg/m3 increase
(minimum to 90th percentile) in the 5-day
moving average of 8-hr maximum PM10 was
9.66 (95% CI, 2.80–33.2) among subjects
not on anti-inﬂammatory medications, com-
pared with 2.96 (95% CI, 0.32–27.0) among
subjects on anti-inflammatory medications.
The OR for a 58-ppb increase (minimum to
90th percentile) in the 1-hr maximum O3 was
4.14 (95% CI, 1.71–10.0) among subjects
not on anti-inﬂammatory medications, com-
pared with 1.20 (95% CI, 0.46–3.15) among
subjects on anti-inflammatory medications.
Heterogeneity in effects of other pollutant
variables and fungal spores was similar. Air
pollution levels were higher then (mean 8-hr
PM10, 43 ± 12 µg/m3; mean O3, 90 ± 18
ppb), possibly explaining stronger associations
than in the present study (Table 4).
Several other panel studies have exam-
ined the importance of medication use to air
pollutant associations (2,25–27). Two of
these studies showed stronger associations
between asthma outcomes and air pollutants
among subjects taking any asthma medica-
tion versus subjects not taking asthma med-
ication, but they did not separate subjects by
anti-inflammatory medication use (25,26).
Mortimer et al. (27) reported results of a
series of 2-week asthma panels in 846 inner-
city children. They compared effects on
asthma outcomes by outdoor O3 levels across
medication groups based on baseline data for
prescribed medication. Associations between
incidence of symptoms and an increase of 15
ppb in O3 were largest among those pre-
scribed cromolyn but not steroids (OR, 1.46;
95% CI, 1.06–2.01) followed by nonsigniﬁ-
cant ORs for those prescribed β-agonists or
xanthines only (1.18), steroids (1.08), and no
medication (1.04). The percent change in
peak expiratory ﬂow (PEF) was also greatest
among those prescribed cromolyn but not
steroids (OR, –1.27%; 95% CI = –2.47to
–0.06) followed by nonsignificant PEF
changes of around –0.5% for the other
groups. Ostro et al. (2) reported results of an
asthma panel study of 138 African-American
children living in Los Angeles and Pasadena,
California. Diary reports of daily and new-
onset presence or absence of wheezing,
cough, and dyspnea were associated with 
3-day lagged 24-hr average PM10 and
Alternaria spores. For an interquartile
increase in 24-hr PM10 of 17 µg/m3, the OR
ranged from 1.10 to 1.30 in subjects with
anti-inflammatory prescriptions and from
1.09 to 1.26 in subjects without such med-
ications. For an interquartile increase in
Alternaria of 20 spores/m3, the OR ranged
from 1.05 to 1.19 in subjects with anti-
inﬂammatory prescriptions and from 0.98 to
1.10 in subjects without such medications.
In summary, there is little consistency
between the present study and the few other
epidemiologic studies examining medication
subgroups, possibly because of methodologic
differences in the stratification of groups.
One major difference is the assessment of
medication used at baseline rather than dur-
ing the days of panel follow-up. If a subject is
not taking an anti-inflammatory medication
during follow-up, putting that subject in the
medication category is exposure misclassiﬁca-
tion. When outcome data are analyzed as
repeated measures, capturing repeated clini-
cal determinants is critically important.
It is biologically plausible that an asth-
matic individual taking anti-inflammatory
medications would be less susceptible to air
pollution health effects that act through
proinﬂammatory mechanisms. Experimental
evidence in asthmatic patients identifies the
proinflammatory effects of O3 as a major
mechanism for adverse effects of O3 in asth-
matic populations (4,5). The proinflamma-
tory nature of PM components is beginning
to be clarified, but the large number of
organic and inorganic components makes
this a major task. Studies examining the
proinflammatory effects of the polycyclic
aromatic hydrocarbon fraction of diesel
exhaust particles serve as an important exam-
ple [reviewed in Nel et al. (28)]. The proin-
flammatory effects of NO2 have also been
described [reviewed in Bascom et al. (19) and
Chauhan et al. (29)]. Four experimental
studies of mild atopic asthmatic adults have
shown an enhancement of airway responses
to allergens after exposure to 260–400 ppb
NO2 (30–33). There is also some evidence
that NO2 exposure leads to persistent neu-
trophilic infiltration in human airways (34)
and to increased histamine release in histo-
cultured human nasal mucosa (35). The
inﬂammatory mechanisms of pollen and fun-
gal allergens in allergic respiratory disease
have also been described (36–38). Our ﬁnd-
ing of a divergence of association in the med-
ication groups for aeroallergens is not
unexpected and demonstrates the value of
stratifying panel data.
Effect modification by respiratory infec-
tions. Our finding that positive associations
between asthma symptom severity and air
pollution is greater during respiratory infec-
tions is supported by experimental data.
Rodent models have shown reduced particle
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induced death, and adverse pulmonary
responses when pulmonary infections are
concurrent with inhalation of PM, including
diesel particles and metal-rich particles
(39–41). There is also some experimental evi-
dence that NO2 exposure leads to an alter-
ation of lymphocyte subsets and diminution
of macrophage inactivation of respiratory
viruses (29). These effects could enhance the
severity of the infectious illness, which in turn
could lower the threshold of the asthmatic
response to inhaled pollutants. A recent epi-
demiologic study by Linaker et al. (42) of
114 asthmatic children using weekly averaged
NO2 levels from personal passive diffusion
samplers showed an increased risk of asthma
episodes after respiratory infections that
occurred when NO2 concentrations were
higher. Some other coherent data can be
found in aggregate time-series data showing
associations of increased levels of PM and/or
NO2 with a) hospitalization for pneumonia
(43), b) hospitalization for respiratory infec-
tions in aggregate (44), c) increased physician
visits for croup in children (45), d) mortality
from pneumonia (46,47), and e) mortality
from respiratory infections in aggregate (48).
The prevailing view here is that air pollution
may have enhanced the severity of ongoing
infectious illness, leading to hospitalization or
mortality.
Effects of NO2. The respiratory health
effects of NO2 on asthma are not entirely
clear, and there are inconsistencies in the
experimental literature. Some studies have
shown alterations in lung function, airway
responsiveness, or symptoms, whereas others
have not, even at high concentrations
[reviewed in Bascom et al. (19)]. In addition
to the study by Linaker et al. (42) discussed
above, another panel study of 30 asthmatic
children found that PEF throughout the day
was inversely associated with outdoor home
NO2 levels, whereas only morning PEF was
inversely associated with indoor bedroom
NO2 levels (49). Several epidemiologic time-
series studies have shown an increase in risk
of asthma hospital admissions or emergency
department visits with increases in outdoor
NO2 levels (44,50–55), but many more have
reported either no results or results that were
nonsignificant for NO2. This inconsistency
may be because of exposure misclassiﬁcation
due to the high spatial variability of NO2,
which is strongly influenced by local traffic
density (56). The site of the monitoring sta-
tion in the present study was generally
upwind (east) of a two-lane highway access-
ing a small residential district (343 vehicles/
day) (57) and was 0.19 mile away and 270
feet higher than an interstate freeway.
Although it is possible that on some days
local trafﬁc could have inﬂuenced NO2 levels,
most of the NO2 measured at the monitoring
station and in the semirural study area is
likely transported along with other copollu-
tants from urban areas of San Diego County.
This means that local temporal inﬂuences on
the central site are not likely to be major limi-
tations to the use of NO2 measurements in
the present study.
Pollutant interactions. We found statisti-
cal interactions between PM10 and NO2 and
between O3 and NO2. Copollutant models,
however, generally resulted in multicollinear-
ity problems, making interpretation of inter-
action terms problematic. It is possible that
joint elevations in two air pollutant types
were acting as an indicator for more causal
particle- and gas-phase components at the
inversion elevation zone of the study region,
but we have no supporting aerometric data.
Most other epidemiologic research to date has
also not been able to attribute the proportion
of adverse respiratory effects to any single air
pollutant, which is not inconsistent with the
view that a mix of air pollutants may be to
some extent acting synergistically (58). A sim-
ple explanation is that at some jointly high
concentrations, the human lung may not be
able handle the total pollutant burden con-
tained in the inspired air. Despite a general
lack of statistical interaction in observational
studies, unmeasured joint effects have been
proposed as one explanation for greater rela-
tive effects of O3 on lung function in epi-
demiologic studies compared with clinical
studies (59).
Effects of fungi and pollen. Associations
between aeroallergens and symptoms were
more robust for total pollen than for total
fungi in the sensitivity analysis. March and
April, the season of study, are the peak polli-
nation months for the native plants in the
area of study, where native dry-land brush
and canyon trees predominate around the res-
idential areas where subjects lived. One of the
original aims of the study was to test the
putative interaction between O3 and pollen
that has been suggested in experimental stud-
ies (9,10). However, there were no pollu-
tant–aeroallergen interactions, which is
consistent with our previous studies in south-
ern California in other months of the year
with lower pollen counts but equally high
fungal spore counts (1,7,8). Although effect
magnitudes of the air pollutants were in some
cases reduced when regressed with the aeroal-
lergens, this was not the case when interac-
tion terms for PM10 and NO2 or for O3 and
NO2 were included in the models. This sug-
gests that causal components of the pollutant
mix were acting independently of aeroaller-
gens. Our previous asthma panel studies did
not ﬁnd confounding of air pollutant associa-
tions by outdoor pollen or fungi (1,7,8).
Several time-series investigations have found
associations between asthma hospital admis-
sions and both outdoor air pollutants (parti-
cles, NO2, or O3) and pollen or fungi, but
none has found any confounding between
aeroallergens and these pollutants (54,60,61).
In two studies, there was evidence that SO2,
NO2, and O3 enhanced the effect of grass
pollen on asthma admissions (54,60),
although there was a negative interaction
between O3 and tree pollen in one of these
studies (54). The general inconsistency
between epidemiologic and experimental data
on the enhancement of allergen-induced respi-
ratory responses by air pollutants may be
explained by a lack of temporally resolved data
to account for hourly exposures and a lack of
spatially resolved data to account for personal
exposures to pollutants and aeroallergens.
Conclusions
We have found associations of asthma symp-
toms in schoolchildren with air pollutants
and aeroallergens. A few observed days drove
stronger associations of symptoms with 1-hr
maximum PM10, but overall, longer averag-
ing times showed more robust associations.
The enhancement of exposure–response rela-
tionships in subjects not taking anti-inflam-
matory medications is consistent with
experimental data on the inflammatory
mechanisms of pollutants and allergens. Our
findings are clinically relevant in that the
symptom response was deﬁned as symptoms
that subjects perceived to have interfered with
regular daily activities. We have no informa-
tion to confirm whether these symptom
responses stemmed from enhancements of
pulmonary inflammation, although signifi-
cant interactions of pollutants with respira-
tory infections suggest that.
Pollutant associations were found at rela-
tively low concentrations and were largely
driven by the top exposure quintiles.
Ultraﬁne particles and secondary air pollutant
gases and organic aerosols above the base of
the temperature inversion layer could be
important in these associations found at low
mass concentrations of PM10. Could some of
these unmeasured pollutants have been the
underlying causal agents? Further investiga-
tions addressing this question may yield clues.
Our view is that the next phase of epi-
demiologic research is to more accurately
quantify both respiratory responses and air-
borne exposures in asthmatic children. This
includes a) the use of biomarkers of response
that better capture underlying inflammatory
processes in asthma, b) the use of better spa-
tially and temporally resolved data that take
into account personal time–place–activity
patterns and hourly exposures, and c) mea-
surements of pollutant components suggested
in experimental data to be causally related to
irritant and immune responses.
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